Literature DB >> 22517684

Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.

Yangfan Zheng1, Manghong Zhu, Sathish Srinivasan, Jerome C Nwachukwu, Valerie Cavett, Jian Min, Kathryn E Carlson, Pengcheng Wang, Chune Dong, John A Katzenellenbogen, Kendall W Nettles, Hai-Bing Zhou.   

Abstract

Previously, we discovered estrogen receptor (ER) ligands with a novel three-dimensional oxabicyclo[2.2.1]heptene core scaffold and good ER binding affinity act as partial agonists via small alkyl ester substitutions on the bicyclic core that indirectly modulate the critical switch helix in the ER ligand binding domain, helix 12, by interactions with helix 11. This contrasts with the mechanism of action of tamoxifen, which directly pushes helix 12 out of the conformation required for gene activation. We now report that a much larger substitution can be tolerated at this position of the bicyclic core scaffold, namely a phenyl sulfonate group, which defines a novel binding epitope for the estrogen receptor. We prepared an array of 14 oxabicycloheptene sulfonates, varying the phenyl sulfonate group. As with the parent compound, 5,6-bis-(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hept-5-ene-2-sulfonic acid phenyl ester (OBHS), these compounds showed preferential affinity for ERα, and the disposition and size of the phenyl substituents were important determinants of the binding affinity and selectivity of these compounds, with those having ortho substituents giving the highest, and para substituents the lowest affinities for ERα. A few analogues exhibit ERα binding affinities that are comparable to or, in the case of the ortho-chloro analogue, higher than that of OBHS itself. In cell-based studies, we found several compounds with activity profiles comparable to tamoxifen, but acting entirely as indirect antagonists, allosterically interfering with recruitment of coactivator proteins to the receptor. Thus, the OBHS binding epitope represents a novel approach to the development of estrogen receptor antagonists via an indirect mechanism of antagonism.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22517684      PMCID: PMC4301955          DOI: 10.1002/cmdc.201200048

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  44 in total

1.  Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist.

Authors:  A C Pike; A M Brzozowski; R E Hubbard; T Bonn; A G Thorsell; O Engström; J Ljunggren; J A Gustafsson; M Carlquist
Journal:  EMBO J       Date:  1999-09-01       Impact factor: 11.598

2.  Molecular basis of agonism and antagonism in the oestrogen receptor.

Authors:  A M Brzozowski; A C Pike; Z Dauter; R E Hubbard; T Bonn; O Engström; L Ohman; G L Greene; J A Gustafsson; M Carlquist
Journal:  Nature       Date:  1997-10-16       Impact factor: 49.962

Review 3.  Bazedoxifene (Wyeth).

Authors:  Christian Gruber; Doris Gruber
Journal:  Curr Opin Investig Drugs       Date:  2004-10

4.  Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.

Authors:  Anh Nguyen; Siden Top; Pascal Pigeon; Anne Vessières; Elizabeth A Hillard; Marie-Aude Plamont; Michel Huché; Clara Rigamonti; Gérard Jaouen
Journal:  Chemistry       Date:  2009       Impact factor: 5.236

5.  The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

Authors:  A K Shiau; D Barstad; P M Loria; L Cheng; P J Kushner; D A Agard; G L Greene
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

6.  Bisphenol A interacts with the estrogen receptor alpha in a distinct manner from estradiol.

Authors:  J C Gould; L S Leonard; S C Maness; B L Wagner; K Conner; T Zacharewski; S Safe; D P McDonnell; K W Gaido
Journal:  Mol Cell Endocrinol       Date:  1998-07-25       Impact factor: 4.102

7.  Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta.

Authors:  Filippo Minutolo; Simone Bertini; Carlotta Granchi; Teresa Marchitiello; Giovanni Prota; Simona Rapposelli; Tiziano Tuccinardi; Adriano Martinelli; Jillian R Gunther; Kathryn E Carlson; John A Katzenellenbogen; Marco Macchia
Journal:  J Med Chem       Date:  2009-02-12       Impact factor: 7.446

8.  Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity.

Authors:  Hai-Bing Zhou; Kathryn E Carlson; Fabio Stossi; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  Bioorg Med Chem Lett       Date:  2008-11-06       Impact factor: 2.823

9.  A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines.

Authors:  Damian Plazuk; Anne Vessières; Elizabeth A Hillard; Olivier Buriez; Eric Labbé; Pascal Pigeon; Marie-Aude Plamont; Christian Amatore; Janusz Zakrzewski; Gérard Jaouen
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 10.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

View more
  13 in total

1.  Selenophenes: Introducing a New Element into the Core of Non-Steroidal Estrogen Receptor Ligands.

Authors:  Silong Zhang; Zhiyong Wang; Zhiye Hu; Changhao Li; Chu Tang; Kathryn E Carlson; Junjie Luo; Chune Dong; John A Katzenellenbogen; Jian Huang; Hai-Bing Zhou
Journal:  ChemMedChem       Date:  2017-01-09       Impact factor: 3.466

Review 2.  Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.

Authors:  John A Katzenellenbogen; Christopher G Mayne; Benita S Katzenellenbogen; Geoffrey L Greene; Sarat Chandarlapaty
Journal:  Nat Rev Cancer       Date:  2018-06       Impact factor: 60.716

3.  Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.

Authors:  Jian Min; Valeria Sanabria Guillen; Abhishek Sharma; Yuechao Zhao; Yvonne Ziegler; Ping Gong; Christopher G Mayne; Sathish Srinivasan; Sung Hoon Kim; Kathryn E Carlson; Kendall W Nettles; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2017-07-14       Impact factor: 7.446

4.  Exploring the Structural Compliancy versus Specificity of the Estrogen Receptor Using Isomeric Three-Dimensional Ligands.

Authors:  Naina Sharma; Kathryn E Carlson; Jerome C Nwachukwu; Sathish Srinivasan; Abhishek Sharma; Kendall W Nettles; John A Katzenellenbogen
Journal:  ACS Chem Biol       Date:  2016-12-29       Impact factor: 5.100

5.  Effects of vaginal conjugated equine estrogens and ospemifene on the rat vaginal wall and lower urinary tract.

Authors:  P Antonio Maldonado; T Ignacio Montoya; Jesus F Acevedo; Patrick W Keller; R Ann Word
Journal:  Biol Reprod       Date:  2017-01-01       Impact factor: 4.285

6.  Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides.

Authors:  Manghong Zhu; Chen Zhang; Jerome C Nwachukwu; Sathish Srinivasan; Valerie Cavett; Yangfan Zheng; Kathryn E Carlson; Chune Dong; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal:  Org Biomol Chem       Date:  2012-11-21       Impact factor: 3.876

7.  Thiophene-core estrogen receptor ligands having superagonist activity.

Authors:  Jian Min; Pengcheng Wang; Sathish Srinivasan; Jerome C Nwachukwu; Pu Guo; Minjian Huang; Kathryn E Carlson; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal:  J Med Chem       Date:  2013-04-15       Impact factor: 7.446

8.  Predictive features of ligand-specific signaling through the estrogen receptor.

Authors:  Jerome C Nwachukwu; Sathish Srinivasan; Yangfan Zheng; Song Wang; Jian Min; Chune Dong; Zongquan Liao; Jason Nowak; Nicholas J Wright; René Houtman; Kathryn E Carlson; Jatinder S Josan; Olivier Elemento; John A Katzenellenbogen; Hai-Bing Zhou; Kendall W Nettles
Journal:  Mol Syst Biol       Date:  2016-04-22       Impact factor: 11.429

9.  Designer antiandrogens join the race against drug resistance.

Authors:  Jatinder S Josan; John A Katzenellenbogen
Journal:  Elife       Date:  2013-04-09       Impact factor: 8.140

10.  Triaryl-substituted Schiff bases are high-affinity subtype-selective ligands for the estrogen receptor.

Authors:  Zong-Quan Liao; Chune Dong; Kathryn E Carlson; Sathish Srinivasan; Jerome C Nwachukwu; Robert W Chesnut; Abhishek Sharma; Kendall W Nettles; John A Katzenellenbogen; Hai-Bing Zhou
Journal:  J Med Chem       Date:  2014-04-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.